Skip to main content

Arcturus Therapeutics Holdings Inc 8-K, filed Nov 5, 2026

Arcturus Therapeutics Holdings Inc. (ARCT)

8-K 2026-11-05 For: 2026-11-05
View Original
Added on November 05, 2026

About this 8-K

Arcturus Therapeutics Holdings Inc filed this 8-K on November 5, 2026.

Arcturus reported a net loss of $7.4 million for the three months ended September 30, 2026, compared with $13.4 million a year earlier, after recognizing the $12.0 million termination payment from CSL Seqirus. Cash and cash equivalents were $184.8 million at September 30, 2026. The company plans ARCT-032 Phase 2 data presentation in Q2 2027. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits